Article

Evaluation of NTRK3 mutation and a mutation-based gene set as biomarkers for immunotherapy outcomes in multiple cancers

2025-11-24

Abstract excerpt

<title>Abstract</title> <p>Introduction: Immune checkpoint blockade (ICB) biomarkers like PD-L1 and TMB have limited utility. This study explores NTRK3 mutation as a novel ICB outcome biomarker and establishes a mutation-based gene set to optimize treatment decisions across cancers. Methods We analyzed immune landscapes of NTRK3 mutations using multi-omics data from TCGA pan-cancer cohorts (discovery cohort, n =...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d022b418-3369-5810-b29f-a76811d5d28f
DOI: 10.21203/rs.3.rs-7437970/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Evaluation of NTRK3 mutation and a mutation-based gene set as biomarkers for immunotherapy outcomes in multiple cancersDOI 10.21203/rs.3.rs-7437970/v1Read

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint InhibitorsSemantic proximity Read

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read

TMBpred: A bioinformatics tool for precise prediction of the Tumor Mutation Burden in 14 cancer typesSemantic proximity Read

Cancer-specific associations of driver genes with immunotherapy outcomeSemantic proximity Read

Identifying survival of pan-cancer patients under immunotherapy using genomic mutation signature with large sample cohorts.Semantic proximity Read

Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials.Semantic proximity Read

Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancerSemantic proximity Read

Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors.Semantic proximity Read

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations.Semantic proximity Read

Functional and sensitivity profiling of the <i>KIT</i> Mutation Landscape in MelanomaSemantic proximity Read

Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy.Semantic proximity Read